| Contributors |
|
xiii | |
| Preface |
|
xvii | |
| Acknowledgments |
|
xix | |
|
1 Engineering solutions to design CAR-T cells |
|
|
1 | (32) |
|
|
|
|
|
|
|
|
|
2 | (6) |
|
2 Pharmacological aspects of CAR-T cells |
|
|
8 | (2) |
|
3 What can be engineered in CAR T-cells? |
|
|
10 | (7) |
|
4 Gene delivery to engineer CAR-T cells |
|
|
17 | (6) |
|
5 Universal/SUPRA CAR-T cells |
|
|
23 | (1) |
|
6 Critical aspects for clinical development |
|
|
23 | (2) |
|
|
|
25 | (1) |
|
|
|
26 | (7) |
|
2 Engineered microbes for cancer immunotherapy |
|
|
33 | (30) |
|
|
|
|
|
|
|
|
|
1 Microbes as tumor immunotherapy |
|
|
33 | (5) |
|
2 Application of synthetic biology to therapeutics |
|
|
38 | (5) |
|
3 Synthetic biology techniques to engineer safety and control growth |
|
|
43 | (3) |
|
4 Application of synthetic biology to engineer microbial therapeutics for cancer |
|
|
46 | (8) |
|
5 Regulatory considerations in the development of engineered bacteria as therapeutics |
|
|
54 | (2) |
|
|
|
56 | (1) |
|
|
|
56 | (7) |
|
3 Polymeric scaffolds for antitumor immune cell priming |
|
|
63 | (34) |
|
|
|
|
|
|
|
|
|
63 | (3) |
|
2 Polymeric materials and scaffold systems |
|
|
66 | (9) |
|
3 Polymeric scaffolds for DC priming and activation |
|
|
75 | (6) |
|
4 Polymeric scaffolds for T-cell activation |
|
|
81 | (5) |
|
5 Conclusion and future perspectives |
|
|
86 | (1) |
|
|
|
87 | (10) |
|
4 Biomaterials and devices for immunotherapy |
|
|
97 | (38) |
|
|
|
|
|
|
|
|
|
|
|
98 | (1) |
|
2 Immunotherapy and chemotherapy combinations |
|
|
99 | (9) |
|
3 Nanoscale biomaterial-based strategies applied |
|
|
108 | (5) |
|
4 Introduction to micro/nanorobots |
|
|
113 | (2) |
|
5 Propulsion engines for MNRs |
|
|
115 | (3) |
|
|
|
118 | (5) |
|
7 Conclusion and future outlook |
|
|
123 | (2) |
|
|
|
125 | (10) |
|
5 Engineered devices for tumor microenvironment immune modulation |
|
|
135 | (20) |
|
|
|
|
|
|
|
135 | (1) |
|
2 Local delivery of engineered devices for tumor immune modulation |
|
|
136 | (9) |
|
3 Transdermal delivery of engineered devices for tumor immune modulation |
|
|
145 | (4) |
|
4 Systemic delivery of engineered devices for tumor immune modulation |
|
|
149 | (2) |
|
5 Limitations, perspectives and future work |
|
|
151 | (1) |
|
|
|
152 | (3) |
|
6 Tumor-on-a-chip devices for cancer immunotherapy |
|
|
155 | (42) |
|
|
|
|
|
|
|
155 | (2) |
|
|
|
157 | (4) |
|
3 Recapitulating the tumor microenvironment |
|
|
161 | (10) |
|
4 Predicating therapeutic efficacy |
|
|
171 | (3) |
|
5 Production of therapeutic cells |
|
|
174 | (7) |
|
|
|
181 | (3) |
|
|
|
184 | (1) |
|
|
|
185 | (12) |
|
7 Challenges and opportunities of nanotechnology in cancer immunotherapy |
|
|
197 | (44) |
|
|
|
|
|
|
|
|
|
1 Background in cancer immunotherapy |
|
|
197 | (2) |
|
2 Immunogenic cell death with nanotechnology |
|
|
199 | (10) |
|
3 Vaccination with nanotechnology |
|
|
209 | (7) |
|
4 Activation of innate immunity |
|
|
216 | (9) |
|
|
|
225 | (5) |
|
|
|
230 | (4) |
|
|
|
234 | (1) |
|
|
|
234 | (7) |
|
8 Stromal modulation strategies to improve immunotherapy response in cancer |
|
|
241 | (52) |
|
|
|
|
|
241 | (4) |
|
2 Tumor stroma mediated immunosuppression |
|
|
245 | (17) |
|
3 Stromal modulation strategies with nanotechnology to improve immunotherapy |
|
|
262 | (18) |
|
|
|
280 | (1) |
|
|
|
281 | (1) |
|
|
|
281 | (12) |
|
9 Spatial mapping of the tumor immune microenvironment |
|
|
293 | (38) |
|
|
|
|
|
|
|
|
|
|
|
|
|
293 | (2) |
|
2 Conventional tissue preparation and processing for cancer histology |
|
|
295 | (4) |
|
3 Mapping proteins and transcripts in the TIME |
|
|
299 | (11) |
|
|
|
310 | (10) |
|
5 Conclusions and future prospects |
|
|
320 | (1) |
|
|
|
321 | (1) |
|
|
|
321 | (10) |
|
10 Nucleic acid biomarker technology for cancer immunotherapy |
|
|
331 | (26) |
|
|
|
|
|
|
|
|
|
|
|
331 | (1) |
|
|
|
332 | (7) |
|
3 Transcriptional signatures |
|
|
339 | (4) |
|
|
|
343 | (1) |
|
|
|
344 | (1) |
|
6 Current challenges in immunogenomics |
|
|
345 | (1) |
|
|
|
345 | (1) |
|
|
|
346 | (1) |
|
|
|
346 | (11) |
|
11 Proteomic biomarker technology for cancer immunotherapy |
|
|
357 | (42) |
|
|
|
|
|
|
|
|
|
|
|
1 Introduction and background |
|
|
358 | (4) |
|
|
|
362 | (21) |
|
3 Proteomic analysis of immune-related adverse events |
|
|
383 | (3) |
|
4 Discussion and future directions |
|
|
386 | (2) |
|
|
|
388 | (11) |
|
12 Personalized cancer immunotherapy |
|
|
399 | (28) |
|
|
|
|
|
|
|
1 Part I. Identifying immune checkpoint blockade therapy-responsive patients |
|
|
399 | (4) |
|
2 Biomarkers based on tumor "foreignness" |
|
|
403 | (3) |
|
3 Tumor immune microenvironment and immunotherapy response |
|
|
406 | (1) |
|
4 "Omics" technologies in personalized immunooncology |
|
|
407 | (1) |
|
5 Immunotherapy response biomarkers not directly measured in tumor |
|
|
408 | (1) |
|
6 Integrating biomarkers to reach "precision" and tailor therapy to patient's unique immunome |
|
|
408 | (2) |
|
7 Part II. Highly personalized immunotherapy |
|
|
410 | (1) |
|
8 Adoptive T cell transfer: A highly personalized therapy for human cancers |
|
|
410 | (1) |
|
9 Tumor-infiltrating lymphocytes: A rich source of tumor specific T cells |
|
|
411 | (3) |
|
10 Tumor neoantigens and their role in tumor immunity |
|
|
414 | (3) |
|
11 Neoantigen reactive T cells; broadening the landscape of personalized cancer immunotherapies |
|
|
417 | (1) |
|
|
|
418 | (1) |
|
13 Neoantigen-specific T cells for adoptive cellular therapies |
|
|
419 | (1) |
|
|
|
420 | (1) |
|
|
|
420 | (7) |
|
13 Image-guided cancer immunotherapy |
|
|
427 | (42) |
|
|
|
|
|
|
|
427 | (1) |
|
2 Clinically relevant imaging modalities to assess anatomic and functional tumor response |
|
|
428 | (2) |
|
3 Imaging approaches to probe the immune system |
|
|
430 | (2) |
|
4 Imaging targets for immunotherapy |
|
|
432 | (10) |
|
5 Imaging of other immune targets |
|
|
442 | (1) |
|
6 Imaging immune cellular subsets |
|
|
442 | (12) |
|
7 Imaging to guide bispecific T-cell engager therapy (BiTE) |
|
|
454 | (1) |
|
8 Image-guided interventional immunotherapies |
|
|
454 | (2) |
|
9 Summary and future directions |
|
|
456 | (1) |
|
|
|
456 | (11) |
|
|
|
467 | (2) |
|
14 Clinical translation and challenges in cancer immunotherapies |
|
|
469 | (19) |
|
|
|
|
|
469 | (1) |
|
2 Challenges in developing cancer immunotherapies |
|
|
470 | (12) |
|
3 Drug development considerations for clinical translation |
|
|
482 | (5) |
|
|
|
487 | (1) |
| References |
|
488 | (3) |
| Index |
|
491 | |
Daugiau apie elektronines knygas